Navigation Links
Intarcia Therapeutics, Inc. Announces Appointment of Kenneth Luskey, M.D. as Vice President, Clinical Research
Date:9/9/2008

HAYWARD, Calif., Sept. 9 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced the appointment of Kenneth Luskey, M.D. to the newly created position of Vice President, Clinical Research reporting to K. Alice Leung, the Company's CEO. In his new role, Dr. Luskey will lead the clinical development of Intarcia's proprietary drug development programs including Omega DUROS(R) therapy for hepatitis C and ITCA 650 for the treatment of type 2 diabetes.

(Logo: http://www.newscom.com/cgi-bin/prnh/20050301/SFTU126LOGO)

Dr. Luskey has extensive experience in endocrinology and metabolism research, as well as in drug development. He spent more than 13 years in academic medicine prior to holding leadership positions with several biopharmaceutical companies where he directed the development of new therapies for the treatment of diabetes. Dr. Luskey began his career at the National Institutes of Health before completing a fellowship and receiving a faculty appointment at the University of Texas Southwestern Medical School. While in Dallas, he worked extensively with Drs. Joseph L. Goldstein and Michael Brown, winners of the Nobel Prize in Medicine in 1985 for their work on cholesterol metabolism. In 1991, Dr. Luskey joined Scios, Inc. (now a member of the Johnson & Johnson family of companies) where he led research efforts to develop new treatments for diabetes and obesity. Subsequently, Dr. Luskey joined Metabolex, Inc. where he led research and drug development programs focused on diabetes and impaired glucose tolerance as Vice President, Clinical Development. Dr. Luskey also was head of experimental medicine for Tularik Inc. (subsequently acquired by Amgen Inc.), and was most recently head of preclinical and translational medicine for Nuvelo, Inc. Dr. Luskey received his medical education at the University of Texas Southwestern Medical School in Dallas. He trained in in
'/>"/>

SOURCE Intarcia Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Cell Therapeutics, Inc. Announces Reverse Stock Split
2. Cell Therapeutics, Inc.s Second Quarter 2008 Financial Results
3. Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results
4. Zenobia Therapeutics, Inc. Receives Michael J. Fox Foundation for Parkinsons Research Award for Work on PD-implicated Protein LRRK2
5. Cell Therapeutics, Inc. Announces Single Institutional Investor to Purchase $44.5 Million of Units Consisting of Senior Convertible Notes and Warrants
6. Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company
7. Shareholders Approve All Matters Proposed by Cell Therapeutics, Inc. at Special Meeting in Lieu of Annual Meeting of Shareholders
8. Cell Therapeutics, Inc. Repays $11.0 million Balance of 2008 Convertible Debt
9. Cell Therapeutics, Inc. Special Meeting in Lieu of Annual Meeting of Shareholders Scheduled for Thursday, June 19, 2008
10. Cell Therapeutics, Inc. Announces Issuance of 2011 Convertible Senior Notes and Common Stock Warrants to a Single Institutional Investor
11. Anesiva and Transcription Factor Therapeutics, Inc. Announce Licensing Agreement for Development and Commercialization of NF-kappa B Clinical Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/21/2014)... (PRWEB) November 20, 2014 Author Matthew ... Walk to the Other Side” published as a ... Finalist in the “Fiction: Short Story” category of the ... Keen, President and CEO of USA Book News, said ... and independent publishers, including Simon & Schuster, Penguin, John ...
(Date:11/21/2014)... 20, 2014 The November 2014 issue ... an open access journal featuring the following articles:, ... to preserve photoresponsiveness in the retina , ... situ hybridization using chromogenic substrates in zebrafish , ... and protein electrophoresis , Nuclear LC3-positive puncta ...
(Date:11/21/2014)... Dallas, Texas (PRWEB) November 21, 2014 ... China Sodium Ferrocyanide Industry” is a professional and ... it provides Sodium ferrocyanide information, like its ... well as industry overview. This report covers the ... well as global (such as the US, Europe, ...
(Date:11/21/2014)... /CNW/ - Aequus Pharmaceuticals Inc. (the "Company" or ... closed a brokered private placement offering (the "Brokered ... Cormark Securities Inc. and Clarus Securities Inc. acted ... a syndicate of agents that also included Wolverton ... "Agents"). Concurrently with the Brokered Offering, the Company ...
Breaking Biology Technology:Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 2Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 3Mystic Ink 's Short Story Collection “A Short Walk to the Other Side” Honoring Ray Bradbury Praised As Award-Winning Finalist In USA Best Book Awards 4BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 2BioTechniques: The International Journal of Life Science Methods Announces the Publication of the November 2014 Issue—Available in Print and Online 3Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3Aequus Pharmaceuticals closes $4.2 million private placement financing 2Aequus Pharmaceuticals closes $4.2 million private placement financing 3
... Iowa, Dec. 18 - DuPont today congratulated,growers planting ... of,the 15 national categories in the 2007 National ... these growers won with Pioneer sorghum,hybrid 84G62., ... in all,five national contest segments. First-, second- and ...
... PALO ALTO, Calif., Dec. 18 CV Therapeutics,Inc. ... U.S. Food and Drug,Administration (FDA) has approved new ... tablets) which describes the ability,of ranolazine to inhibit ... Published data on ranolazine,s mechanism suggests that during ...
... Md., Dec. 18 Panacea Pharmaceuticals, lung,cancer ... one of Time Magazine,s,Ten Biggest Medical Breakthroughs ... please cut,and paste into browser:, http://www.time.com/time/specials/2007/top10/article/0,30583,1686204_1686252_1690390, ,00.html) ... to facilitate the identification,of lung cancer, even ...
Cached Biology Technology:DuPont Congratulates Growers Planting Pioneer(R) Brand Sorghum Hybrids in Winning Majority of National Categories in Yield Contest 2FDA Approves New Mechanism of Action Labeling for Ranexa(R) 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 2Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 3Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 4
(Date:11/10/2014)... pods began appearing on U.S. store shelves in early ... ever since. The small packets can be tossed into ... a liquid or powder. The convenience, though, has come ... from researchers at Nationwide Children,s Hospital found that from ... of 17,230 children younger than 6 years of age ...
(Date:11/6/2014)... yet progress in preventing and treating migratory cancer ... challenging to design drugs that work against metastasis," ... at Harvard Medical School. , "Unfortunately, many ... , Gujral and colleagues have now identified a ... how metastasis begins. Their findings may also inform ...
(Date:11/5/2014)... de Janeiro, Brazil -Individuals show great diversity in their ... males and females greatly differ in their perceptual evaluation ... of smell tests. , Sex differences in ... behaviors and may be connected to one,s perception of ... emotions. Thus, women,s olfactory superiority has been suggested to ...
Breaking Biology News(10 mins):Study finds laundry detergent pods, serious poisoning risk for children 2Migration negation 2Migration negation 3The female nose always knows: Do women have more olfactory neurons? 2
... "It,s in their genes" is a common refrain from ... age 100 and beyond. Up until now, research has ... as high levels of HDL ("good") cholesterol. But researchers at ... Graduate School of Psychology of Yeshiva University have found ...
... have discovered that some hardy species can survive the ... submersible rises to the surface. The team,s findings, published ... can be inadvertently carried by submersibles to new areas, ... using the manned submersible Alvin to collect samples of ...
... DURHAM, N.C. Women receiving care for breast ... for years after they have completed treatment, according to ... Center. The findings, reported online in the ... that poor cardio-pulmonary function may be a strong predictor ...
Cached Biology News:'Personality genes' may help account for longevity 2Deep sea animals stowaway on submarines and reach new territory 2Cardio fitness levels of breast cancer patients may affect survival 2
... The standard electrophoresis hood ... gel documentation systems. Placed on ... camera in place and provides ... photography on the lab bench. ...
... microarrays are derived from frozen embedded tissue ... control procedures to ensure the highest quality. ... in one block, sectioned at a thickness ... slides. Sections are large (3-5 mm in ...
... derived from Paraffin embedded tissue blocks, which ... to ensure the highest quality. Tissues of ... block, sectioned at a thickness of 5 ... are large (3-5 mm in diameter) in ...
... tissue microarrays are derived from Paraffin embedded ... quality control procedures to ensure the highest ... assembled in one block, sectioned at a ... coated slides. Sections are large (3-5mm in ...
Biology Products: